Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK – Vertex Pharmaceuticals

  1. Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK  Vertex Pharmaceuticals
  2. Vertex announces Registration of ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class CFTR Modulator for the…

Continue Reading